


A distinct innate immune signature marks progression from mild to severe COVID-19

Graphical Abstract



Authors

Stéphane Chevrier, Yves Zurbuchen, Carlo Cervia, ..., Jakob Nilsson, Onur Boyman, Bernd Bodenmiller

Correspondence

jakob.nilsson@uzh.ch (J.N.),
onur.boyman@uzh.ch (O.B.),
bernd.bodenmiller@uzh.ch (B.B.)

In Brief

Chevrier et al. characterize the innate immune response in mild and severe COVID-19 patients and healthy individuals by mass cytometry and serum proteomics. They demonstrate profound phenotypic changes after SARS-CoV-2 infection and ongoing inflammation, with an innate signature switch in severe COVID-19 patients late in the disease course.

Highlights

- Systems analysis of the innate immune responses in COVID-19 up to 47 days after onset
- Surge of CD169⁺ and depletion of CD16⁺CD14⁻ monocytes early after symptom onset
- High levels of inflammatory cytokines and immature neutrophils in severe COVID-19
- Persistent inflammation in late severe cases, while normalization in mild cases



Article

A distinct innate immune signature marks progression from mild to severe COVID-19

Stéphane Chevrier,^{1,2,10} Yves Zurbuchen,^{3,10} Carlo Cervia,^{3,10} Sarah Adamo,³ Miro E. Raeber,³ Natalie de Souza,^{1,2,4} Sujana Sivapatham,^{1,2} Andrea Jacobs,^{1,2} Esther Bachli,⁵ Alain Rudiger,⁶ Melina Stüssi-Helbling,⁷ Lars C. Huber,⁷ Dominik J. Schaer,⁸ Jakob Nilsson,^{3,10,*} Onur Boyman,^{3,9,10,*} and Bernd Bodenmiller^{1,2,10,11,*}

¹Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland

²Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland

³Department of Immunology, University Hospital Zurich (USZ), Zurich, Switzerland

⁴Institute for Molecular Systems Biology, ETH Zurich, Zurich, Switzerland

⁵Clinic for Internal Medicine, Uster Hospital, Uster, Switzerland

⁶Department of Medicine, Limmattal Hospital, Schlieren, Switzerland

⁷Clinic for Internal Medicine, City Hospital Triemli Zurich, Zurich, Switzerland

⁸Department of Internal Medicine, University Hospital Zurich (USZ), Zurich, Switzerland

⁹Faculty of Medicine, University of Zurich, Zurich, Switzerland

¹⁰These authors contributed equally

¹¹Lead contact

*Correspondence: jakob.nilsson@uzh.ch (J.N.), onur.boyman@uzh.ch (O.B.), bernd.bodenmiller@uzh.ch (B.B.)

<https://doi.org/10.1016/j.xcrm.2020.100166>

SUMMARY

Coronavirus disease 2019 (COVID-19) manifests with a range of severities, but immune signatures of mild and severe disease are still not fully understood. Here, we use mass cytometry and targeted proteomics to profile the innate immune response of patients with mild or severe COVID-19 and of healthy individuals. Sampling at different stages allows us to reconstruct a pseudo-temporal trajectory of the innate response. A surge of CD169⁺ monocytes associated with an IFN- γ ⁺MCP-2⁺ signature rapidly follows symptom onset. At later stages, we observe a persistent inflammatory phenotype in patients with severe disease, dominated by high CCL3 and CCL4 abundance correlating with the re-appearance of CD16⁺ monocytes, whereas the response of mild COVID-19 patients normalizes. Our data provide insights into the dynamic nature of inflammatory responses in COVID-19 patients and identify sustained innate immune responses as a likely mechanism in severe patients, thus supporting the investigation of targeted interventions in severe COVID-19.

INTRODUCTION

Coronavirus disease 2019 (COVID-19) was first identified in December 2019 in Wuhan, China.¹ The disease developed into a global pandemic, with 60 million confirmed cases and close to 1.5 million confirmed deaths as of the end of November 2020.² The clinical presentation of COVID-19 can vary from asymptomatic cases to an acute respiratory distress syndrome (ARDS), requiring mechanical ventilation.³ Approximately 5% of those clinically diagnosed with COVID-19 develop ARDS and generally experience a sudden deterioration after ~1 week of symptom onset.⁴

Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), a positive-sense, single-stranded RNA virus, has been identified as the causative pathogen of COVID-19. This virus shows a tropism for cells expressing the angiotensin-converting enzyme 2, which serves as an entry receptor for SARS-CoV-2 into cells of the respiratory tract, kidneys, liver, heart, brain, and blood vessels.⁵ Upon infection of epithelial cells, pattern recognition receptors that sense viral RNA initiate interferon (IFN) production and innate immune cell recruitment, triggering

an inflammatory response that has also been linked to inflammatory activation in COVID-19.^{6,7}

Early data indicated that patients with severe disease mount a strong inflammatory response, as shown by increased levels of proinflammatory cytokines, such as tumor necrosis factor (TNF), monocyte chemoattractant protein 1 (MCP-1/CCL2), and macrophage inflammatory protein 1 α (MIP-1 α /CCL3).⁸ Other studies further revealed a distinct cytokine response with activated interleukin-1 (IL-1) and IL-6 pathways as well as chemokine-enriched signatures.^{9,10} Type I IFN response during SARS and SARS-CoV-2 infection has gained particular attention since a deficient or delayed type I IFN response may be associated with a severe disease course as observed in patients with inborn errors in type I IFN response or with neutralizing autoantibodies against type I IFN.^{11–16}

Myeloid cells have been implicated in the pathophysiology of COVID-19 by contributing to local tissue damage and as potential producers of cytokines that lead to the hyperinflammatory state seen in severe COVID-19.^{17–19} Studies applying high-dimensional single-cell analysis have shown distinct phenotypic changes within the monocytic compartment in patients with



COVID-19.^{20,21} A recent single-cell RNA-sequencing study of bronchoalveolar lavage fluid showed changes in the local myeloid environment toward a proinflammatory, peripheral monocyte-derived phenotype and a depletion of alveolar macrophages in severe COVID-19 patients.²²

These data suggest a distinct role of the myeloid compartment in the pathogenesis of COVID-19; however, these studies have focused mainly on the early disease course of the infection, and data on the cellular innate immune response combined with the underlying cytokine and chemokine network, at high phenotypic and temporal resolution, are still sparse. Here, we describe an in-depth, cross-sectional characterization of the myeloid compartment in 66 patients with mild to severe COVID-19 and 22 healthy controls by using 40-parameter mass cytometry and targeted proteomics up to 47 days after symptom onset. Using this systems approach, we could reconstruct phenotypic changes arising throughout the course of the disease both in mild and severe patients.

RESULTS

Clinicopathological assessment of patients with mild versus severe COVID-19

To better understand the role of the myeloid compartment in the pathophysiology of COVID-19, we established a multicenter cohort, comprising 66 COVID-19 patients. At blood sampling, 28 patients were classified as mild COVID-19 with either mild flu-like illness or mild pneumonia, whereas 38 patients were classified as severe COVID-19 experiencing severe pneumonia or ARDS (Figure 1A; Table 1).²³ The patient outcomes were prospectively recorded, and one individual died of COVID-19. Samples of 22 healthy donors were included in the study as controls. Patients suffering from severe disease were on average older than those with mild disease (Figure 1B; Table 1), which is consistent with previously published results.³ Furthermore, hypertension and heart disease were significantly associated with a severe disease course (Table 1).

The laboratory findings at admission revealed a prominent inflammatory state for patients with both mild and severe disease, as evidenced by higher levels of C-reactive protein (CRP) and pathological values of lactate dehydrogenase (LDH) in mild and severe COVID-19 patients (Table S1). Complete differential blood counts showed normal white blood cell counts (WBCs), despite significant changes in the granulocyte subsets, with an increase in neutrophils in severe COVID-19 patients and a decrease in basophils and eosinophils in both mild and severe COVID-19 patients compared to healthy controls (Figure 1B; Table S1). Natural killer (NK) cell cytopenia in the CD3⁻CD56^{bright}CD16^{dim} population was also associated with a severe disease course (Figure 1B; Table S1), confirming previous publications.^{24–26} A correlation map that included additional clinical metadata of COVID-19 patients revealed that high CRP and neutrophil counts positively correlate with measures of disease severity, whereas lymphocytes and NK cells show an inverse relationship to these parameters (Figure 1C). Thus, we could recapitulate the strong inflammatory state, the changes in the complete blood count, and the prolonged clinical course before deterioration, which make COVID-19 a distinct disease.²⁷

Systems-wide profiling of innate compartment in COVID-19 patients

To comprehensively characterize the innate immune response against SARS-CoV-2, we took a systems-level approach based on mass cytometry and targeted proteomics (Figure 1A). We used a 40-plex mass cytometry panel designed to identify main immune cell types and further characterize myeloid cell subsets in depth (Key Resources Table; Figures S1A–S1D). The main cell types were identified using a random forest classifier trained on manually gated cells from a representative subset of data (Figure S1E). The cell annotation was consistent with the t-distributed stochastic neighbor embedding (t-SNE) map visualization (Figures 1D and S1F) and the expression of canonical markers (Figure 1E). In line with previous reports,²⁶ we observed a decrease in T cell frequencies in severe COVID-19 cases compared to mild cases and healthy controls, which was accompanied by an increased monocyte frequency (Figure 1F). Since peripheral blood mononuclear cells (PBMCs) were isolated following a density gradient separation, only low-density neutrophils were included in the analysis. Consistent with a previous report,²⁸ this subset was present at very low frequency in healthy controls but increased in patients infected with SARS-CoV-2, accounting for >50% of the PBMCs in some patients (Figure 1F).

Different myeloid landscape in patients with mild and severe COVID-19

Neutrophils have been reported to play a key role in the development of severe COVID-19. In particular, a high neutrophil:lymphocyte ratio has been associated with poor clinical outcomes, and a CD16^{int}CD44^{low}CD11b^{int} low-density neutrophil population, associated with high IL-6 and TNF concentrations, was increased in severe COVID-19 patients compared to healthy controls.²⁸ To assess the low-density neutrophil subsets in our cohort, we used t-SNE to visualize the expression of relevant markers on this cell type (Figure 2A). Although all cells were positive for the canonical neutrophil markers CD15 and CD66ace, differences in the abundance of CD11b, CD11c, and CD16 were observed. Visualizing the disease status on the t-SNE map revealed an enrichment of CD16^{low} neutrophils in patients with severe disease (Figure 2B). To confirm this observation, we classified neutrophils into CD16^{hi}, CD16^{int}, and CD16^{low} populations based on manual annotation of PhenoGraph clusters (Figures S2A and S2B). The proportion of CD16^{low} neutrophils was significantly higher in patients with severe disease than in the other 2 groups (Figure 2C). The CD16^{low} subset was associated with an increased proliferation rate, based on Ki-67 expression (Figures 2A and S2C). Since mature neutrophils do not proliferate in the periphery, this observation indicates the release of immature or alternatively activated neutrophils into the circulation, consistent with their CD11b^{low}CD16^{low} phenotype.^{29–31}

To characterize the phenotypic diversity in the monocytic compartment across the cohort, we visualized the myeloid-related markers on the t-SNE map of the monocyte population (Figure 2D). To identify monocyte subsets in an unsupervised way, we performed automated clustering using the PhenoGraph algorithm, which led to the identification of 13 distinct cell subsets (Figure 2E). Clusters M1–M7 were characterized by a high




Figure 1. Experimental approach, clinical characteristics, and identification of the main immune cell types in COVID-19 patients based on mass cytometry

(A) Schematic of the study design of the cohort.

(B) Boxplots showing the age distribution, selected clinical parameters at admission, and the NK cell counts in the patient cohort split by disease severity (n = 22 healthy controls, 28 mild COVID-19 patients, and 38 severe COVID-19 patients).

(C) Correlation map of the indicated parameters and clinical features grouped by a hierarchical clustering on the COVID-19 patients. The circle color reflects the magnitude of the Pearson's correlation coefficient (red indicates positive correlation, blue indicates negative correlation). Asterisks represent the statistically significant correlations (*p < 0.05, **p < 0.01, ***p < 0.001).

(D) t-SNE plot of a random subset of 1,000 immune cells of the mass cytometry analysis from each sample (n = 78 individuals) colored by main cell types as identified based on a random forest cell classification.

(E) Heatmap of the normalized marker expression in the main cell types. Relative abundances of each cell type are plotted to the right of the heatmap.

(F) Boxplots comparing the frequencies of the indicated cell types in healthy controls and patients with mild and severe disease.

Statistical analyses were performed with a Mann-Whitney-Wilcoxon test corrected for multiple testing using the Holm method, and p values are shown if the results were significant (p < 0.05).

Table 1. Clinical and laboratory characteristics of the healthy controls and the COVID-19 patients

Disease severity ^a	Healthy controls (n = 22)	Mild cases (n = 28)		Severe cases (n = 38)			
		Mild illness	Mild pneumonia	Severe pneumonia	Mild ARDS	Moderate ARDS	Severe ARDS
Disease grade ^b							
Grade at sampling, no.	–	18	10	20	7	7	4
Maximal grade, no.	–	16	8	19	7	8	8
Characteristics							
Age, y, median (IQR)	32.50 (29.25–48.0)	50.5 (34.50–60.25) ^d		67.5 (59.0–79.0) ^{c,d}			
Gender, M/F	11/11	12/16		24/14			
Time after symptom onset, days	–	12.86 ± 10.71		20.21 ± 11.96 ^c			
Level of care at blood sampling							
Outpatient, no. (%)	–	14 (50)		–			
Inpatient, no. (%)	–	14 (50)		38 (100) ^c			
Ward, no. (%)	–	14 (50)		28 (73.7)			
Respiratory support ^e required, no. (%)	–	–		36 (94.7)			
ICU, no. (%)	–	–		10 (26.3)			
Comorbidities							
Hypertension, no. (%)	–	7 (25)		22 (57.9) ^c			
Diabetes, no. (%)	1 (4.5)	4 (14.3)		12 (31.6)			
Heart disease, no. (%)	–	3 (10.7)		17 (44.7) ^c			
Cerebrovascular disease, no. (%)	–	1 (3.6)		4 (10.5)			
Lung disease, no. (%)	–	3 (10.7)		6 (15.8)			
Kidney disease, no. (%)	–	7 (25)		10 (26.3)			
Malignancy, no. (%)	–	–		4 (10.5)			
Systemic immunosuppression, no. (%)	–	3 (10.7)		4 (10.5)			
Outcome							
Released/recovered, no. (%)	–	28 (100)		37 (97.4)			
Death, no. (%)	–	–		1 (2.6)			

IQR, interquartile range.

^aCOVID-19 disease severity at the time of blood sample collection. Mild illness and mild pneumonia are considered mild COVID-19 disease, and severe pneumonia and any grade of ARDS are considered severe COVID-19 disease.

^bCOVID-19 grade according to World Health Organization guidelines, recorded at sampling and prospectively followed until recovery.²³

^cIndicates significance (p value threshold < 0.05) compared to “mild.”

^dIndicates significance in comparison to “healthy”. Mann-Whitney-Wilcoxon test was used to test for differences between continuous variables adjusted for multiple testing using the Holm method. Categorical variables were compared between “mild” and “severe” using Fisher’s exact test.

^eSupplemental oxygen, non-invasive ventilation, or mechanical ventilation are considered respiratory support.

abundance of CD14, CD36, and CCR2 and the absence of CD16, corresponding to classical monocytes. Based on CD16 expression and reduced levels of CD14, CCR2, and CD36, M8 and M9 were identified as non-classical (CD16⁺CD14^{dim}) and intermediate (CD16⁺CD14⁺) monocytes, respectively.³² M10–M13 showed an activated CD169⁺ phenotype. While clusters M11–M13 shared similarities with classical monocytes, M10 was closely related to intermediate monocytes (Figure 2F). Strikingly, CD169⁺ activated monocytes (M10–M13) were found exclusively in SARS-CoV-2-infected patients (Figures 2E and 2G). The fact that CD169⁺ monocytes could derive both from classical and intermediate monocytes was supported by a diffusion map analysis (Figures S2D and S2E), which aligns cells along putative developmental trajectories.³³ CD169 upregulation was accompanied by the induction of other activation markers, including CD64, CD68, and CD38, compared to the classical

monocyte clusters M1–M3 (Figure 2G). CD141, which is associated with anticoagulant properties,³⁴ was particularly induced on M11 (Figure 2H). Markers involved in antigen presentation and co-stimulation, including HLA-DR, CD86, TIM-3 and VISTA, progressively decreased in clusters M10–M13, suggesting these clusters were part of a phenotypic continuum (Figures 2G and 2H). Proliferation, based on Ki-67 expression, was found to be induced in these clusters, especially in M12, compared to non-classical or CD169[–] intermediate and classical monocytes (Figures 2G and 2H).

Among CD169[–] classical monocytes, clusters M1–M3 were found predominantly in healthy controls, whereas clusters M4–M7 were mostly found in SARS-CoV-2-infected patients (Figures 2E and 2G). Overall, CD169[–] classical monocytes found in COVID-19 patients tended to express markers associated with activation, including CD38 and CD86, compared to the classical




Figure 2. In-depth characterization of the myeloid cells in the peripheral blood of COVID-19 patients

(A) t-SNE plots of normalized expression of the indicated markers across a maximum of 1,000 neutrophils per patient (n = 22 healthy controls, 27 mild COVID-19 patients, and 29 severe COVID-19 patients).

(B) t-SNE plot generated as indicated in (A) and colored by disease severity.

(C) Left: t-SNE plot generated as indicated in (A) and colored by CD16 expression level based on manual assignment of PhenoGraph clusters. Right: boxplot showing the frequency of CD16^{low} neutrophils in COVID-19 patients and healthy controls. Statistical analyses were performed with a Mann-Whitney-Wilcoxon test corrected for multiple testing using the Holm method, and p values are shown if the results were significant (p < 0.05).

(legend continued on next page)

monocytes found in healthy donors (Figure 2I). Cluster M7, which expressed intermediate levels of CD169, could constitute a stage between CD169⁻ classical monocytes and CD169⁺ classical monocytes. Similar to the M11 CD169⁺ cluster, the M6 cluster displayed an increased expression of thrombomodulin (CD141) and CD163. M4 showed a distinct phenotype with decreased expression of CCR2, HLA-DR, CD38, CD86, and the co-inhibitory receptors TIM-3 and VISTA, consistent with chemotactic paralysis in a murine model.³⁵ In summary, high-dimensional single-cell mass cytometry analysis allowed us to characterize the monocyte compartments of COVID-19 patients and healthy controls with unprecedented depth and to uncover profound changes upon SARS-CoV-2 infection.

Stratification of COVID-19 patients based on monocyte composition

We next assessed the distribution of the 13 identified monocyte clusters across patients. This analysis revealed 3 main groups, which were enriched for either mild COVID-19 patients, healthy controls, or severe cases of COVID-19 (Figure 3A). In the group that included more mild cases, the monocyte compartment consisted almost exclusively of CD169⁺ activated clusters (M10–M13) in different ratios, with only a minor fraction of cells from clusters M4–M7. The healthy controls were relatively homogeneous: ~80% of cells consisted of classical monocytes (M1–M3) and ~15%–20% of cells were intermediate and non-classical monocytes (M9 and M8, respectively), consistent with the literature.³² The group dominated by patients with severe COVID-19 was characterized by a high frequency of distinct classical monocyte subsets (M4–M7), with frequencies of intermediate and non-classical monocytes slightly higher than in the group dominated by healthy controls.

We observed similar patterns when directly comparing differences of the monocyte cluster frequencies in healthy subjects and patients with mild and severe disease (Figure 3B). Most strikingly, the CD169⁺ clusters M10–M13 were completely absent in healthy controls. Conversely, the classical monocyte clusters M1–M3 were present at high abundance in healthy donors, at lower abundance in patients with mild disease, and at intermediate abundance in patients with severe disease. The HLA-DR^{low} CCR2^{low} and the CD141⁺ monocytes (M4 and M6, respectively) were virtually absent in healthy controls and were present at higher abundance in patients with severe than in mild disease, while the phenotypically similar M5 monocytes originated mainly from a single patient with severe illness. The non-classical (M8) and intermediate monocytes (M9) were significantly reduced in patients with mild disease compared to

healthy controls and were present at higher abundance in a subset of patients with severe disease than in healthy controls. To exclude a confounding effect due to age or gender differences between the severity groups, we compared the cluster frequencies in the different age and gender groups. While non-classical (M8) and intermediate (M9) monocytes increased slightly with age in both COVID-19 patients and healthy controls, which is consistent with the literature,³⁷ we could not observe any evident age or gender association for the other clusters (Figures S3A and S3B).

To gain further insight into the relationship between the innate immune signature and disease status, we performed a principal-component analysis (PCA) of monocyte and neutrophil cluster frequencies across the cohort and found that the first two principal components enabled the stratification of subjects based on disease status (Figure 3C, top panel). A biplot graph displaying simultaneously the subjects as dots and the contribution of the different cell types on the principal components as arrows revealed a strong association between clusters M1–M3 and healthy controls (Figure 3C, bottom panel). A group dominated by mild patients was characterized by a high abundance of clusters M10–M13. A more heterogeneous set of predominantly severe COVID-19 cases was defined by a higher abundance of the clusters M4–M6, M8, and M9, as well as by CD16^{low} low-density neutrophils. A correlative analysis performed across innate cell subsets and patients confirmed the pattern observed based on the PCA analysis (Figure S3C). Thus, despite the expected diversity across individuals, these multiparametric analyses identified innate immune signatures that stratified different groups of patients. However, this stratification could be only partly explained by disease severity, suggesting that other factors are also at play.

Changes in innate cell frequencies over the course of SARS-CoV-2 infection

Since the samples for different patients were collected at different points in their disease course, the time component is likely to have an influence on the cell cluster composition. To investigate this possibility, we plotted the different cell type frequencies as a function of time after symptom onset. The total monocyte compartment remained relatively constant over the disease course, while the low-density neutrophils tended to increase in COVID-19 patients, compared to healthy controls early after symptom onset, before their counts went back to baseline values at later stages of the disease (Figure 4A). These changes were accompanied by a decrease in CD16^{hi} neutrophils over time in patients with severe disease, whereas CD16^{low} neutrophils remained consistently high (Figure 4B).

(D) t-SNE plots of normalized expression of the indicated markers across a maximum of 1,000 monocytes per patient.

(E) t-SNE plots generated as indicated in (D) colored by disease severity (top) and by clusters identified with the PhenoGraph algorithm (bottom).

(F) Contour plots showing the distribution of a subset of 10,000 cells from the indicated clusters for a selected set of markers. For this analysis, classical monocytes M1–M7 were merged in a single cluster.

(G) Heatmap of the normalized marker expression in PhenoGraph monocyte clusters. The frequency of each cluster in patients with mild and severe disease and in healthy controls is indicated as a stacked histogram to the right of the heatmap. Cell numbers for each cluster are plotted to the right of the stacked histogram.

(H) Overlaid histograms showing arcsinh transformed counts on a linear axis for selected markers for the CD169⁺-activated monocyte clusters.

(I) Overlaid histograms showing arcsinh transformed counts on a linear axis for the indicated markers for the classical monocyte clusters. Values in the plot indicate median untransformed count intensities.

In (H) and (I), values on the plot indicate the median raw ion count intensity for each cluster and marker indicated.




Figure 3. Patient stratification based on myeloid signature

(A) Stacked histogram of the PhenoGraph monocyte clusters per patient ($n = 75$ individuals), ordered by cluster composition similarities. Disease severity and grade for each patient are shown on top of the stacked histogram.

(B) Boxplots of frequencies of the indicated monocyte clusters in the different disease severities. Statistical analyses were performed with a Mann-Whitney-Wilcoxon test corrected for multiple testing based on the Holm method, and p values are shown if the results were significant ($p < 0.05$).

(C) Top: principal-component analysis (PCA) of monocyte and neutrophil cluster frequencies and myeloid immune cell subset frequencies across the cohort. The PCA plot (top) shows the first 2 principal components separating the samples. The percentage of explained variance for each component is shown in brackets. Each dot represents a patient, colored by disease status. A concentration ellipse and the mean point are shown for each group. Bottom: biplot displaying simultaneously the observations (patients) as gray dots and the variables (cell subsets) as vectors.³⁶ Vectors indicate the direction and strength of each cell component to the overall distribution. Variables grouping together are positively correlated.




Figure 4. Myeloid cell frequencies over the course of the SARS-CoV-2 infection

(A–C) Scatterplot of indicated subset frequencies of (A) total PBMCs, (B) total neutrophils, and (C) total monocytes, relative to time after symptom onset. The dots are colored by disease grade at sampling time ($n = 75$ individuals). The frequencies in healthy controls are shown as a reference on the left, with a horizontal line indicating the median. The pseudo-time course was modeled using a generalized additive model for the disease severities separately (mild, blue lines; severe, red lines). p values of generalized additive models using time as a covariate were calculated for both the mild (blue) and severe (red) patient group and are shown when significant ($p < 0.05$).

(legend continued on next page)

The monocyte clusters M1–M13 also showed distinct changes over the disease course. Classical monocytes typically found in healthy controls (M1–M3) were observed at very low frequencies in mild and severe cases sampled early during the disease course but gradually increased in patients sampled later (Figure 4C, purple frame). The frequencies of these clusters tended to remain at lower levels than in the healthy controls even as late as 47 days after symptom onset. In contrast, frequencies of disease-specific CD169[−] classical monocytes (M4 and M6) increased during the disease course of severe COVID-19 cases, peaking at ~3 weeks after symptom onset (Figure 4C, purple frame). Intriguingly, mild COVID-19 cases with increased frequencies of cluster M4 corresponded to patients who required hospitalization or showed prolonged symptoms (Figure S4A).

The activated CD169⁺ monocyte clusters M10–M13 were present at high frequencies early during the disease course (Figure 4C, orange frame). Within the first 20 days after symptom onset, the monocyte compartment was strongly dominated by this phenotype, which decreased thereafter and was undetectable in most patients sampled >20 days after symptom onset. This pattern was similar in mild and severe COVID-19, suggesting that the time after symptom onset had a stronger influence on CD169⁺-activated cluster frequency than disease severity.

The non-classical (M8) and intermediate (M9) monocyte clusters were virtually absent early upon viral infection (Figure 4C, green frame). The initial reduction was followed by their recovery at later stages, showing a trend toward higher frequencies in patients with severe compared to mild disease for both clusters. This finding could be explained in part by the fact that severe COVID-19 patients tend to be older (Figure S3A).

The disappearance of non-classical monocytes and the increase of CD169⁺ cells among classical, intermediate, and non-classical subset at early time points was confirmed based on a manual gating approach (Figure 4D, S4B, and S4C). Using this strategy, we further investigated the evolution of marker expression in classical monocytes throughout the disease course and found that the quick induction of CD169 was accompanied by the upregulation of CD141, CD38, indoleamine 2,3-dioxygenase (IDO), and Ki-67, which is consistent with the fact that these markers are predominantly found in CD169⁺-activated clusters (Figure 4E). In summary, the analysis of cluster frequencies in relation to the time after symptom onset revealed distinct dynamic patterns of monocyte frequencies in patients with mild and severe disease, which were most obvious at later stages.

Temporal changes in cytokine signatures in COVID-19 patients

Monocyte development, homeostasis, and fate are strongly interlinked with the cytokine and chemokine environment. To probe potential correlates to the changes seen in the myeloid compartment during COVID-19 progression, we used the targeted prote-

omics Olink assay to measure 92 inflammation-associated serum proteins. The comparison of data from healthy controls and patients with severe COVID-19 showed a strong upregulation of proinflammatory cytokines and chemokines (Figure 5A). IL-6, TNF, IFN- γ , and IL-18 were significantly upregulated (false discovery rate [FDR] 1%) in patients with severe disease (Figure 5A) consistent with previous reports.^{9,10} The elevated concentrations of IL-18 and LDH may indicate a contribution of inflammasome activation,^{7,13,18} although we did not detect an increase in IL-1 β (Figure S5A).

Several chemokines important for myeloid cell trafficking were significantly upregulated in patients with severe COVID-19. These chemokines included MCP-1, an IFN-stimulated gene (ISG), MCP-2, MCP-3, CX3CL1 (chemotactic for non-classical monocytes), CXCL1 (a potent neutrophil-recruiting chemokine), the more promiscuous CCL3 and CCL4, and macrophage-colony-stimulating factor (M-CSF), which is crucial for myeloid precursor survival and lineage commitment (Figure 5A).^{38,39}

Distinct expression patterns emerged by plotting cytokine expression versus time after symptom onset. In comparison to healthy controls, IFN- γ and MCP-2 were present at significantly higher concentrations in patients with severe disease sampled early after symptom onset but returned to near normal values later in the disease course. Interestingly, in the mild group, concentrations of proinflammatory cytokines remained lower in patients with mild illness compared to individuals with pneumonia (Figure 5B). Consistent with ELISA measurements, M-CSF, IL-6, and TNF were present at higher concentrations in patients with severe disease compared to mild disease; these cytokines tended to be present at high concentrations throughout the disease course in patients with severe disease, whereas a decrease was observed in patients with mild symptoms as the disease progressed (Figures 5B and S5A). The chemokines CXCL1, CX3CL1, MCP-1, and MCP-3 were significantly increased compared to healthy controls in patients with severe COVID-19 independent of time after symptom onset (Figure S5B). In striking contrast, CCL3 and CCL4 were not elevated in the first days of the disease but were significantly increased at later stages in patients with severe disease (Figure 5B). These time-dependent changes were confirmed with a differential expression analysis and by binning the time after symptom onset (Figures S5C and S5D).⁴⁰ In summary, these results are indicative of a more exacerbated inflammatory phenotype late during the disease course in patients with severe disease than in those with mild symptoms.

Temporal correlation of cytokine signatures and innate cell subsets

To better understand the interplay between these serum proteins and innate immune cell subsets, we performed a hierarchical clustering on a correlation map of all significantly changed (FDR 1%) serum proteins, immune cell subsets, and myeloid

(D) Contour plots showing expression of CD14 and CD16 on monocytes from a representative sample of a healthy donor as well as an early- and late-stage patient (left column). Gates and percentage of cells in each gate for classical, intermediate, and non-classical monocytes are indicated for each sample. Expression of CD169 in each gate for each sample is displayed as overlaid histograms on the left.

(E) Scatterplots of indicated marker median ion count (MIC) in the classical monocyte gate relative to the time after symptom onset. Dots are colored by disease grade at sampling time and healthy controls are displayed in green on the left as reference.




Figure 5. Cytokine signature shift between early and late stages of disease

(A) Volcano plot of the Olink proteomics data comparing the healthy control data ($n = 17$) to that from patients with severe COVID-19 ($n = 35$). An FDR of 1% was taken as significance cutoff. The identity is given for factors reaching significance, with the color code indicated on the right.

(B) Scatterplot of serum protein expression levels relative to the time after symptom onset. Plotted is normalized protein expression (NPX) on a log₂ scale. The dots are colored by disease grade at sampling time ($n = 77$ individuals). The expression levels of the healthy controls are shown as a reference on the left, with a horizontal line indicating the median. The pseudo-time course was modeled as described in Figure 4A, and p values are shown when significant ($p < 0.05$).

clusters (Figure S6A). This approach demonstrated a strong association of the activated CD169⁺ monocyte clusters M10–M13 with proinflammatory cytokines, including IFN- γ , MCP-2, IL-18, and IL-6, as well as an association of the disease-related CD169⁻ classical monocyte clusters M4 and M6 with transforming growth factor- α (TGF- α), CCL3, and CCL4. To further understand these relationships in the context of the patients in our cohort, we performed PCA. A biplot graph revealed that certain combinations of cell types and soluble factors stratified patients and healthy controls (Figures 6A and 6B). One group, dominated by patients with mild symptoms and patients sampled early in the disease course, was defined by activated CD169⁺ monocytes (M10–M13) in combination with MCP-2 and IFN- γ . A second group of patients, enriched for more severe, late-stage cases, was defined primarily by disease-related CD169⁻ classical monocytes (M4–M6) in combination with CCL3, CCL4, and CCL23 (Figures 6A and 6B). The healthy donors were defined by classical monocytes (clusters M1–M3) and were located close to the majority of late-stage mild patients. Intermediate (M9) and non-classical (M8) monocytes contributed to both healthy and severe groups. These data strongly suggest an innate signature shift between the early and late stages of the disease, leading to a divergence of patients with mild and severe COVID-19 over the disease course. While the former become similar to healthy controls, the latter exhibit signs of hyperinflammation.

To further characterize the relationships between monocyte subsets and soluble factors identified in the PCA, we performed a direct correlation between the cluster frequencies and cytokine levels. There was a strong correlation between the activated Ki-67⁺ monocyte cluster M12 and M-CSF, IFN- γ , IL-6, and TNF, which was most evident in early-stage patients (Figures 6C and S6B). We also found that the non-classical monocyte M8 and the intermediate monocyte cluster M9 were strongly correlated with CCL3 and CCL4, but in this case the correlation was most prominent in late-stage patients (Figures 6C, right column, and S6C). These results suggest that the inflammatory environ-

ment found in late stages of COVID-19 is predominantly associated with the presence of the intermediate monocytes.

To determine whether the switch in signatures observed in our pseudo-temporal analysis could be observed in individual patients over time, we compared the cluster frequencies and cytokine levels in 4 patients who were sampled twice. We confirmed that the frequencies of the activated CD169⁺ clusters M10–M13 were reduced, and the frequencies of the non-classical (M8) and intermediate (M9) monocytes were increased over time (Figure 6D). Confirming our pseudo-longitudinal analysis, we observed decreases in IFN- γ and MCP-2 over time in these re-sampled patients, accompanied by increases in CCL3 and CCL4 (Figure 6E). These observations were also confirmed in a separate, publicly available, longitudinal dataset of 37 hospitalized COVID-19 patients (Figure S6D).²⁴ Overall, these data suggest there is a coordinated change from a signature characterized by a high abundance of activated CD169⁺ monocytes, IFN- γ , and MCP-2 to a signature with increased intermediate and non-classical monocytes, CCL3 and CCL4, in the first 2 weeks after SARS-CoV-2 infection. Severe COVID-19 patients showed long-lasting high concentrations of CCL3 and CCL4, demonstrating a marked phenotypic switch.

DISCUSSION

Early in the COVID-19 pandemic, data began to suggest that patients with severe disease show hyperinflammatory immune responses with changes in the myeloid compartment toward a proinflammatory phenotype.^{8,22,41} Using a systems-wide characterization of immune parameters in a multicenter cohort of COVID-19 patients and healthy controls, we identified marked changes in the innate immune signature in SARS-CoV-2-infected individuals.

Among the phenotype changes occurring early upon SARS-CoV-2 infection, we identified a decrease in non-activated classical monocytes, a depletion of non-activated intermediate and




Figure 6. Temporal correlation of cytokine signature and innate cell subsets

(A) Biplot of the first two principal components of a PCA based on monocyte and neutrophil cluster frequencies, myeloid immune cell subset frequencies, and expression values of selected serum proteins. Dots represent the COVID-19 patients and healthy controls ($n = 70$ individuals), and the arrows indicate the direction and strength of each cell and soluble components to the overall distribution. Variables that group together are positively correlated. The percentage of explained variance for each component is shown in brackets.

(B) Scatterplot of the first two principal components of a PCA generated as indicated in (A), colored by the time since symptom onset. The shape of each dot corresponds to the patient groups.

(C) Scatterplots of frequencies of the indicated clusters versus NPX of selected serum proteins in individual patients. The dots indicate data for individual patients colored by disease grade. Relationship between the 2 variables is visualized with a linear regression line and quantified using a Spearman's correlation coefficient (Rho) with the corresponding p value. Fq, frequency.

(D and E) Scatterplots of frequencies of the indicated monocyte clusters (D) or the NPX of the indicated soluble factors (E) as a function of time after symptom onset in individual patients who were sampled twice during the course of the study. Dots are colored by patient number, and lines connect paired samples. Sample indicated with an asterisk was excluded from the cohort analysis due to low cell number.

non-classical monocytes, and a surge of CD169⁺ activated monocytes as well as low-density neutrophils.⁴²

CD169 is quickly induced in a type I IFN-dependent manner on the surface of monocytes upon Epstein-Barr virus (EBV) or human immunodeficiency virus (HIV) infection.^{43,44} CD169 has been found on circulating monocytes in mild COVID-19 patients.^{20,42,45} Furthermore, CD169⁺ monocytes have been shown to have a strong ISG signature in single-cell RNA sequencing (scRNA-seq) data, which is consistent with the in-

duction of ISGs observed in our study, including CD64, CD38, and IDO. We find that this phenotype can also be present in severe COVID-19. Although the fate of these CD169⁺ CCR2⁺ monocytes remains elusive, the recruitment to the lung through the CCR2-CCL2 axis is a possible option, as MCP-1 (CCL2) is significantly upregulated in COVID-19 patients. SARS-CoV mouse models have shown that the recruitment of proinflammatory monocytes to the lungs, promoted by delayed type I IFN signaling, drives immunopathology, and interestingly, a

scRNA-seq study in bronchoalveolar lavage fluid of SARS-CoV-2 infected individuals found an accumulation of monocyte-derived macrophages and high levels of inflammatory cytokines in severe patients.^{16,22} Several factors, such as a maladapted IFN response or an inadequate T cell response in severe COVID-19,⁴⁶ may contribute to the dysregulated monocyte response in severely ill patients. The latter could be due to sub-optimal viral control, although T cells have also been shown to control an overactive innate response in a murine coronavirus infection model.^{47,48}

The reduction of non-classical CD16⁺ monocytes early in the disease course is striking and has been evaluated as a potential marker of severe COVID-19.²⁰ Several mechanisms such as differentiation or migration, potentially dependent on CX3CL1,⁴⁹ could be involved. A recent study in bronchoscopy samples from intensive care unit (ICU)-admitted COVID-19 patients found an enrichment of CD16⁺ monocytes in the lung.⁵⁰ Based on our diffusion map analysis, CD169⁺ monocytes could also arise from CD16⁺ monocytes, similar to what was reported upon simian immunodeficiency virus (SIV) or HIV infection.^{51,52} Intriguingly, we found a tendency toward elevated levels of activated CD169⁺ HLA-DR^{hi} intermediate monocytes in individuals with mild COVID-19, which is of interest as CD16⁺ monocytes are critical for viral sensing. Therefore, a strong response of this subset may be important for an effective adaptive response to be mounted.^{53–55}

Analysis of the inflammatory cytokine and chemokine profile to SARS-CoV-2 infection identified a response dominated by TNF and IL-6, in agreement with a previous report.⁹ The initial inflammatory response was dominated by IFN- γ , MCP-2, M-CSF, and IL-6, which were co-regulated with the activated CD169⁺ monocyte subsets, most prominently with the cluster showing increased proliferation, and the low-density granulocytes. IL-6 and M-CSF contribute to increased hematopoiesis under inflammatory conditions, a process called emergency granulopoiesis,³⁸ potentially explaining the initial increase in activated monocytes and granulocytes after SARS-CoV-2 infection. Alternatively, a small subset of monocytes has been shown to retain proliferative capacity, especially under inflammatory conditions, which may also contribute to the initial surge, as we detected increased Ki-67 positivity in these cells. However, Ki-67 positivity may also be explained by a more immature cell phenotype.^{56–58} Our proteomics panel did not include granulocyte-CSF (G-CSF) and GM-CSF, 2 other cytokines crucially involved in myeloid homeostasis.⁵⁹ Immature granulocytes were increased in severely ill patients, and such dysregulated, emergency granulocytes may contribute to severe COVID-19 pathogenesis, as previously suggested.^{20,21,28}

Late in the disease course, COVID-19 patients with severe disease continued to show signs of ongoing inflammation, including abnormally high levels of TNF. The cellular signature at this stage was driven by a surge of severe COVID-19-associated CD141⁺ CD163⁺ classical monocytes, markers recently associated with severe COVID-19,^{20,21,55} and HLA-DR^{low} CCR2^{low} VISTA^{low} classical monocytes, reminiscent of an immune paralysis phenotype in monocytes. Such dysregulated monocytes may contribute to an insufficient antiviral immune response; however, the phenotype can also be the product of an hyperinflammatory environment.²⁷ We find that the chemokine signature was

dominated by CCL3 and CCL4, which were correlated with the reappearance of intermediate and non-classical monocytes. These CCR5 ligands drive the recruitment of a variety of immune cells such as neutrophils and monocytes, but also adaptive immune cells, and are increased early in the serum and lungs of patients with certain acute respiratory viral infections.^{60,61} In contrast, these chemokines quite distinctly increased late during the disease course in our cohort, and their production at this stage in severe COVID-19 seems to be a correlate of ongoing local inflammation and may contribute to tissue damage. Both chemokines have been shown to be produced on a transcriptional level by monocytes isolated from the lungs of severe COVID-19 patients.^{13,22}

In summary, our systems-level analysis of the innate immune response to SARS-CoV-2 shows that there are profound changes in the peripheral monocyte compartment of COVID-19 patients, with a previously underappreciated temporal dynamic. Even though patients with mild and severe disease showed similar phenotypic changes early after symptom onset, we found a stronger inflammatory phenotype throughout the disease course of patients experiencing severe symptoms, and could show for the first time that severe COVID-19 patients had a distinct innate signature at later stages of the disease. These results provide evidence for a strong inflammatory response to SARS-CoV-2 infection, further supporting the investigation of targeted interventions in severe cases of COVID-19.¹⁸ The distinct temporal changes in immune signatures indicate that specific interventions may benefit from precise timing to maximize therapeutic efficacy.^{59,62}

Limitations of study

A limitation of our study is that the cellular trajectories identified during acute infection rely on cross-sectional samples collected from patients at different times after symptom onset. We were able to analyze only 4 patients in a longitudinal manner, but confirmed our findings by analyzing a publicly available longitudinal dataset,²⁴ which provided strong support for our pseudo-temporal analysis.

Another limitation of the study is that the different groups could not be completely age and gender matched due to COVID-19-associated clinical risk factors. However, our analyses revealed that time after symptom onset and disease severity are the key factors that explain signature shifts upon SARS-CoV-2 infection. Furthermore, mild COVID-19 patients are underrepresented at time points later than 30 days after symptom onset, which reduces the statistical power of our analyses.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
 - Lead contact
 - Materials availability
 - Data and code availability

- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
- **METHOD DETAILS**
 - Blood collection and sample preparation for CyTOF
 - Mass cytometry barcoding
 - Antibodies and antibody labeling
 - Sample staining and data acquisition
 - Cytokine ELISA
 - Proteomics analysis using Olink
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
 - Mass cytometry data preprocessing and automated cell classification
 - Dimensionality reduction and clustering analysis
 - Statistical analyses

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at <https://doi.org/10.1016/j.xcrm.2020.100166>.

ACKNOWLEDGMENTS

We thank all of the patients for their participation in this study, the teams of the Diagnostic Immunology and the Transplantation Immunology Laboratories at the University Hospital Zurich for their great effort, as well as Alessandra Guaita, Claudia Meloni, Jennifer Jörger, Ulrike Held, Sara Hasler, and the members of the Bodenmiller and Boyman laboratories for their support and helpful discussions. Furthermore, we would like to thank Lucie Rodriguez and Petter Brodin for kindly sharing data. The graphical abstract was created with [BioRender.com](https://www.biorender.com). This work was funded by the Swiss National Science Foundation (4078P0_198431 to O.B., B.B., and J.N. and 310030-172978 to O.B.), the Pandemic Fund of the University of Zurich (to O.B.), the Innovation Fund of the University Hospital Zurich (to O.B.), Swiss Academy of Medical Sciences fellowships (323530-191220 to C.C., 323530-191230 to Y.Z., and 323530-177975 to S.A.), the Young Talents in Clinical Research Fellowship by the Swiss Academy of Medical Sciences and the Bangerter Foundation (YTCR 32/18 to M.E.R.), the Clinical Research Priority Program of the University of Zurich for the CRPP CYTIMM-Z (to O.B.), and a SNSF R'Equip grant (to B.B.).

AUTHOR CONTRIBUTIONS

S.C., Y.Z., and C.C. contributed to the study design, patient recruitment, data collection, analysis, interpretation, and writing of the manuscript. S.S., A.J., and S.C. developed the CyTOF antibody panel and performed the CyTOF experiments. S.A. contributed to the experiments, data collection, analysis, and interpretation. M.E.R., E.B., A.R., M.S.-H., L.C.H., and D.J.S. contributed to patient recruitment and clinical management. N.d.S. contributed to the writing of the manuscript. J.N., O.B., and B.B. contributed to the study conception and design, data analysis, interpretation, and writing of the manuscript. All of the authors reviewed and approved the final version of the manuscript.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: September 4, 2020
Revised: November 11, 2020
Accepted: December 15, 2020
Published: December 26, 2020

REFERENCES

1. Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al.; China Novel Coronavirus Investigating and

- Research Team (2020). A novel coronavirus from patients with pneumonia in China, 2019. *N. Engl. J. Med.* 382, 727–733.
2. Dong, E., Du, H., and Gardner, L. (2020). An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect. Dis.* 20, 533–534.
3. Wu, Z., and McGoogan, J.M. (2020). Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. *JAMA* 323, 1239–1242.
4. Wiersinga, W.J., Rhodes, A., Cheng, A.C., Peacock, S.J., and Prescott, H.C. (2020). Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. *JAMA* 324, 782–793.
5. Puelles, V.G., Lütgehetmann, M., Lindenmeyer, M.T., Sperhake, J.P., Wong, M.N., Allweiss, L., Chilla, S., Heinemann, A., Wanner, N., Liu, S., et al. (2020). Multiorgan and Renal Tropism of SARS-CoV-2. *N. Engl. J. Med.* 383, 590–592.
6. Iwasaki, A., and Medzhitov, R. (2015). Control of adaptive immunity by the innate immune system. *Nat. Immunol.* 16, 343–353.
7. Yap, J.K.Y., Moriyama, M., and Iwasaki, A. (2020). Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19. *J. Immunol.* 205, 307–312.
8. Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 395, 497–506.
9. van de Veerdonk, F.L., Janssen, N.A.F., Grondman, I., de Nooijer, A.H., Koeken, V.A.C.M., Matzaraki, V., Boahen, C.K., Kumar, V., Kox, M., Koenen, H.J.P.M., et al. (2020). A systems approach to inflammation identifies therapeutic targets in SARS-CoV-2 infection. *medRxiv*. <https://doi.org/10.1101/2020.05.23.20110916>.
10. Blanco-Melo, D., Nilsson-Payant, B.E., Liu, W.C., Uhl, S., Hoagland, D., Møller, R., Jordan, T.X., Oishi, K., Panis, M., Sachs, D., et al. (2020). Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. *Cell* 181, 1036–1045.e9.
11. Park, A., and Iwasaki, A. (2020). Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19. *Cell Host Microbe* 27, 870–878.
12. Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., Péré, H., Charbit, B., Bondet, V., Chenevier-Gobeaux, C., et al. (2020). Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. *Science* 369, 718–724.
13. Lee, J.S., Park, S., Jeong, H.W., Ahn, J.Y., Choi, S.J., Lee, H., Choi, B., Nam, S.K., Sa, M., Kwon, J.-S., et al. (2020). Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. *Sci. Immunol.* 5, 1554.
14. Bastard, P., Rosen, L.B., Zhang, Q., Michailidis, E., Hoffmann, H.-H., Zhang, Y., Dorgham, K., Philippot, Q., Rosain, J., Béziat, V., et al. (2020). Auto-antibodies against type I IFNs in patients with life-threatening COVID-19. *Science* 370, eabd4585.
15. Zhang, Q., Bastard, P., Liu, Z., Le Pen, J., Moncada-Velez, M., Chen, J., Ogishi, M., Sabli, I.K.D., Hodeib, S., Korol, C., et al. (2020). Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. *Science* 370, eabd4570.
16. Channappanavar, R., Fehr, A.R., Vijay, R., Mack, M., Zhao, J., Meyerholz, D.K., and Perlman, S. (2016). Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. *Cell Host Microbe* 19, 181–193.
17. McKechnie, J.L., and Blish, C.A. (2020). The Innate Immune System: Fighting on the Front Lines or Fanning the Flames of COVID-19? *Cell Host Microbe* 27, 863–869.
18. Merad, M., and Martin, J.C. (2020). Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. *Nat. Rev. Immunol.* 20, 355–362.

19. Vabret, N., Britton, G.J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M.D., et al. (2020). Immunity 52, 910–941.
20. Silvin, A., Chapuis, N., Dunsmore, G., Goubet, A.-G., Dubuisson, A., Derosa, L., Almire, C., Hénon, C., Kosmider, O., Droin, N., et al. (2020). Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19. *Cell* 182, 1401–1418.e18.
21. Schulte-Schrepping, J., Reusch, N., Paclik, D., Baßler, K., Schlickeiser, S., Zhang, B., Krämer, B., Krammer, T., Brumhard, S., Bonaguro, L., et al.; Deutsche COVID-19 OMICS Initiative (DeCOI) (2020). Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment. *Cell* 182, 1419–1440.e23.
22. Liao, M., Liu, Y., Yuan, J., Wen, Y., Xu, G., Zhao, J., Cheng, L., Li, J., Wang, X., Wang, F., et al. (2020). Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. *Nat. Med.* 26, 842–844.
23. World Health Organization (2020). Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance. <https://www.who.int/publications/i/item/clinical-management-of-covid-19>.
24. Rodriguez, L., Pekkarinen, P.T., Lakshminanth, T., Tan, Z., Consiglio, C.R., Pou, C., Chen, Y., Mugabo, C.H., Nguyen, N.A., Nowlan, K., et al. (2020). Systems-Level Immunomonitoring from Acute to Recovery Phase of Severe COVID-19. *Cell Rep. Med.* 1, 100078.
25. Zhang, J.J., Dong, X., Cao, Y.Y., Yuan, Y.D., Yang, Y.B., Yan, Y.Q., Akdis, C.A., and Gao, Y.D. (2020). Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy* 75, 1730–1741.
26. Kuri-Cervantes, L., Pampena, M.B., Meng, W., Rosenfeld, A.M., Ittner, C.A.G., Weisman, A.R., Agyekum, R.S., Mathew, D., Baxter, A.E., Vella, L.A., et al. (2020). Comprehensive mapping of immune perturbations associated with severe COVID-19. *Sci. Immunol.* 5, eabd7114.
27. Giamarellos-Bourboulis, E.J., Netea, M.G., Rovina, N., Akinosoglou, K., Antoniadou, A., Antonakos, N., Damoraki, G., Gkavogianni, T., Adami, M.E., Katsaounou, P., et al. (2020). Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. *Cell Host Microbe* 27, 992–1000.e3.
28. Morrissey, S.M., Geller, A.E., Hu, X., Tieri, D., Cooke, E.A., Ding, C., Woeste, M., Zhange, H., Cavallazi, R., Clifford, S.P., et al. (2020). Emergence of Low-density Inflammatory Neutrophils Correlates with Hypercoagulable State and Disease Severity in COVID-19 Patients. *medRxiv*. <https://doi.org/10.1101/2020.05.22.20106724>.
29. Scapini, P., Marini, O., Tecchio, C., and Cassatella, M.A. (2016). Human neutrophils in the saga of cellular heterogeneity: insights and open questions. *Immunol. Rev.* 273, 48–60.
30. Ng, L.G., Ostuni, R., and Hidalgo, A. (2019). Heterogeneity of neutrophils. *Nat. Rev. Immunol.* 19, 255–265.
31. Impellizzeri, D., Ridder, F., Raeber, M.E., Egholm, C., Woytschak, J., Kolios, A.G.A., Legler, D.F., and Boyman, O. (2019). IL-4 receptor engagement in human neutrophils impairs their migration and extracellular trap formation. *J. Allergy Clin. Immunol.* 144, 267–279.e4.
32. Thomas, G.D., Hamers, A.A.J., Nakao, C., Marcovecchio, P., Taylor, A.M., McSkimming, C., Nguyen, A.T., McNamara, C.A., and Hedrick, C.C. (2017). Human Blood Monocyte Subsets: A New Gating Strategy Defined Using Cell Surface Markers Identified by Mass Cytometry. *Arterioscler. Thromb. Vasc. Biol.* 37, 1548–1558.
33. Haghverdi, L., Buettner, F., and Theis, F.J. (2015). Diffusion maps for high-dimensional single-cell analysis of differentiation data. *Bioinformatics* 31, 2989–2998.
34. Wang, K.C., Li, Y.H., Shi, G.Y., Tsai, H.W., Luo, C.Y., Cheng, M.H., Ma, C.Y., Hsu, Y.Y., Cheng, T.L., Chang, B.I., et al. (2015). Membrane-Bound Thrombomodulin Regulates Macrophage Inflammation in Abdominal Aortic Aneurysm. *Arterioscler. Thromb. Vasc. Biol.* 35, 2412–2422.
35. Broughton, T.W.K., ElTanbouly, M.A., Schaafsma, E., Deng, J., Sarde, A., Croteau, W., Li, J., Nowak, E.C., Mabaera, R., Smits, N.C., et al. (2019). Defining the Signature of VISTA on Myeloid Cell Chemokine Responsiveness. *Front. Immunol.* 10, 2641.
36. Abdi, H., and Williams, L.J. (2010). Principal component analysis. *Wiley Interdiscip. Rev. Comput. Stat.* 2, 433–459.
37. Seidler, S., Zimmermann, H.W., Bartneck, M., Trautwein, C., and Tacke, F. (2010). Age-dependent alterations of monocyte subsets and monocyte-related chemokine pathways in healthy adults. *BMC Immunol.* 11, 30.
38. Boettcher, S., and Manz, M.G. (2017). Regulation of Inflammation- and Infection-Driven Hematopoiesis. *Trends Immunol.* 38, 345–357.
39. Ginhoux, F., and Jung, S. (2014). Monocytes and macrophages: developmental pathways and tissue homeostasis. *Nat. Rev. Immunol.* 14, 392–404.
40. Prévost, J., Gasser, R., Beaudoin-Bussièrès, G., Richard, J., Duerr, R., Laumaea, A., Anand, S.P., Goyette, G., Benlarbi, M., Ding, S., et al. (2020). Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike. *Cell Rep. Med.* 1, 100126.
41. Wilk, A.J., Rustagi, A., Zhao, N.Q., Roque, J., Martínez-Colón, G.J., McKechnie, J.L., Ivison, G.T., Ranganath, T., Vergara, R., Hollis, T., et al. (2020). A single-cell atlas of the peripheral immune response in patients with severe COVID-19. *Nat. Med.* 26, 1070–1076.
42. Carissimo, G., Xu, W., Kwok, I., Abdad, M.Y., Chan, Y.H., Fong, S.W., Puan, K.J., Lee, C.Y.P., Yeo, N.K.W., Amrun, S.N., et al. (2020). Whole blood immunophenotyping uncovers immature neutrophil-to-VD2 T-cell ratio as an early marker for severe COVID-19. *Nat. Commun.* 11, 5243.
43. Rempel, H., Calosing, C., Sun, B., and Pulliam, L. (2008). Sialoadhesin Expressed on IFN-Induced Monocytes Binds HIV-1 and Enhances Infectivity. *PLoS One* 3, e1967.
44. Farina, A., Peruzzi, G., Lacconi, V., Lenna, S., Quarta, S., Rosato, E., Vestri, A.R., York, M., Dreyfus, D.H., Faggioni, A., et al. (2017). Epstein-Barr virus lytic infection promotes activation of Toll-like receptor 8 innate immune response in systemic sclerosis monocytes. *Arthritis Res. Ther.* 19, 39.
45. Bedin, A.-S., Makinson, A., Picot, M.-C., Mennechet, F., Malergue, F., Pisoni, A., Nyiramigisha, E., Montagnier, L., Bollere, K., Debiesse, S., et al. (2020). Monocyte CD169 expression as a biomarker in the early diagnosis of COVID-19. *medRxiv*. <https://doi.org/10.1101/2020.06.28.20141556>.
46. Adamo, S., Chevrier, S., Cervia, C., Zurbuchen, Y., Raeber, M.E., Yang, L., Sivapatham, S., Jacobs, A., Bächli, E., Rudiger, A., et al. (2020). Lymphopenia-induced T cell proliferation is a hallmark of severe COVID-19. *bioRxiv*. <https://doi.org/10.1101/2020.08.04.236521>.
47. Kim, K.D., Zhao, J., Auh, S., Yang, X., Du, P., Tang, H., and Fu, Y.X. (2007). Adaptive immune cells temper initial innate responses. *Nat. Med.* 13, 1248–1252.
48. Channappanavar, R., and Perlman, S. (2017). Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. *Semin. Immunopathol.* 39, 529–539.
49. Thomas, G., Tacke, R., Hedrick, C.C., and Hanna, R.N. (2015). Nonclassical patrolling monocyte function in the vasculature. *Arterioscler. Thromb. Vasc. Biol.* 35, 1306–1316.
50. Sánchez-Cerrillo, I., Landete, P., Aldave, B., Sánchez-Alonso, S., Sánchez-Azofra, A., Marcos-Jiménez, A., Ávalos, E., Alcaraz-Serna, A., de Los Santos, I., Mateu-Albero, T., et al.; REINMUN-COVID and EDEPIMIC groups (2020). COVID-19 severity associates with pulmonary redistribution of CD1c+ DCs and inflammatory transitional and nonclassical monocytes. *J. Clin. Invest.* 130, 6290–6300.
51. van der Kuyl, A.C., van den Burg, R., Zorgdrager, F., Groot, F., Berkhout, B., and Cornelissen, M. (2007). Sialoadhesin (CD169) Expression in CD14+ Cells Is Upregulated Early after HIV-1 Infection and Increases during Disease Progression. *PLoS One* 2, e257.
52. Kim, W.K., McGary, C.M., Holder, G.E., Filipowicz, A.R., Kim, M.M., Beydoun, H.A., Cai, Y., Liu, X., Sugimoto, C., and Kuroda, M.J. (2015). Increased Expression of CD169 on Blood Monocytes and Its Regulation

- by Virus and CD8 T Cells in Macaque Models of HIV Infection and AIDS. *AIDS Res. Hum. Retroviruses* 31, 696–706.
53. Cros, J., Cagnard, N., Woollard, K., Patey, N., Zhang, S.Y., Senechal, B., Puel, A., Biswas, S.K., Moshous, D., Picard, C., et al. (2010). Human CD14^{dim} monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. *Immunity* 33, 375–386.
 54. Kwissa, M., Nakaya, H.I., Onlamoou, N., Wrammert, J., Villinger, F., Perng, G.C., Yoksan, S., Pattanapanyasat, K., Chokeyhaibulkit, K., Ahmed, R., and Pulendran, B. (2014). Dengue virus infection induces expansion of a CD14⁽⁺⁾CD16⁽⁺⁾ monocyte population that stimulates plasmablast differentiation. *Cell Host Microbe* 16, 115–127.
 55. Kvedaraitė, E., Hertwig, L., Sinha, I., Ponzetta, A., Myrberg, I.H., Lourda, M., Dzidic, M., Akber, M., Klingström, J., Folkesson, E., et al. (2020). Perturbations in the mononuclear phagocyte landscape associated with COVID-19 disease severity. *medRxiv*. <https://doi.org/10.1101/2020.08.25.20181404>.
 56. Clanchy, F.I.L., Holloway, A.C., Lari, R., Cameron, P.U., and Hamilton, J.A. (2006). Detection and properties of the human proliferative monocyte subpopulation. *J. Leukoc. Biol.* 79, 757–766.
 57. Patel, A.A., Zhang, Y., Fullerton, J.N., Boelen, L., Rongvaux, A., Maini, A.A., Bigley, V., Flavell, R.A., Gilroy, D.W., Asquith, B., et al. (2017). The fate and lifespan of human monocyte subsets in steady state and systemic inflammation. *J. Exp. Med.* 214, 1913–1923.
 58. Geissmann, F., Manz, M.G., Jung, S., Sieweke, M.H., Merad, M., and Ley, K. (2010). Development of monocytes, macrophages, and dendritic cells. *Science* 327, 656–661.
 59. Lang, F.M., Lee, K.M.C., Teijaro, J.R., Becher, B., and Hamilton, J.A. (2020). GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches. *Nat. Rev. Immunol.* 20, 507–514.
 60. Melchjorsen, J., Sørensen, L.N., and Paludan, S.R. (2003). Expression and function of chemokines during viral infections: from molecular mechanisms to in vivo function. *J. Leukoc. Biol.* 74, 331–343.
 61. Nuriev, R., and Johansson, C. (2019). Chemokine regulation of inflammation during respiratory syncytial virus infection. *F1000Res.* 8. <https://doi.org/10.12688/f1000research.20061.1>.
 62. The RECOVERY Collaborative Group (2020). Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. *N. Engl. J. Med.* <https://doi.org/10.1056/NEJMoa2021436>.
 63. Chevrier, S., Crowell, H.L., Zanotelli, V.R.T., Engler, S., Robinson, M.D., and Bodenmiller, B. (2018). Compensation of Signal Spillover in Suspension and Imaging Mass Cytometry. *Cell Syst.* 6, 612–620.e5.
 64. Kotecha, N., Krutzik, P.O., and Irish, J.M. (2010). Web-based analysis and publication of flow cytometry experiments. *Curr. Protoc. Cytom. Chapter* 10, 17.
 65. Angerer, P., Haghverdi, L., Büttner, M., Theis, F.J., Marr, C., and Büttner, F. (2016). destiny: diffusion maps for large-scale single-cell data in R. *Bioinformatics* 32, 1241–1243.
 66. Liaw, A., and Wiener, M. (2002). Classification and regression by random Forest. *R News* 2, 18–22.
 67. Levine, J.H., Simonds, E.F., Bendall, S.C., Davis, K.L., Amir, A.D., Tadmor, M.D., Litvin, O., Fienberg, H.G., Jager, A., Zunder, E.R., et al. (2015). Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis. *Cell* 162, 184–197.
 68. van der Maaten, L., and Hinton, G. (2008). Visualizing data using t-SNE. *J. Mach. Learn. Res.* 9, 2579–2605.
 69. Ranieri, V.M., Rubenfeld, G.D., Thompson, B.T., Ferguson, N.D., Caldwell, E., Fan, E., Camporota, L., and Slutsky, A.S.; ARDS Definition Task Force (2012). Acute respiratory distress syndrome: the Berlin Definition. *JAMA* 307, 2526–2533.
 70. Cervia, C., Nilsson, J., Zurbuchen, Y., Valaperti, A., Schreiner, J., Wolfensberger, A., Raeber, M.E., Adamo, S., Weigang, S., Emmenegger, M., et al. (2020). Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. *J. Allergy Clin. Immunol.* <https://doi.org/10.1016/j.jaci.2020.10.040>.
 71. Zunder, E.R., Finck, R., Behbehani, G.K., Amir, A.D., Krishnaswamy, S., Gonzalez, V.D., Lorang, C.G., Bjornson, Z., Spitzer, M.H., Bodenmiller, B., et al. (2015). Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm. *Nat. Protoc.* 10, 316–333.
 72. Zivanovic, N., Jacobs, A., and Bodenmiller, B. (2014). A practical guide to multiplexed mass cytometry. *Curr. Top. Microbiol. Immunol.* 377, 95–109.
 73. Behbehani, G.K., Thom, C., Zunder, E.R., Finck, R., Gaudilliere, B., Fragiadakis, G.K., Fantl, W.J., and Nolan, G.P. (2014). Transient partial permeabilization with saponin enables cellular barcoding prior to surface marker staining. *Cytometry A* 85, 1011–1019.
 74. Catena, R., Özcan, A., Jacobs, A., Chevrier, S., and Bodenmiller, B. (2016). AirLab: a cloud-based platform to manage and share antibody-based single-cell research. *Genome Biol.* 17, 142.
 75. Lundberg, M., Eriksson, A., Tran, B., Assarsson, E., and Fredriksson, S. (2011). Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood. *Nucleic Acids Res.* 39, e102.
 76. Crowell, H.L., Jacobs, A., Tumor Profiler Consortium; Bodenmiller, B., and Robinson, M.D. (2020). An R-based reproducible and user-friendly preprocessing pipeline for CyTOF data. *F1000Res.* 9, 1263.
 77. Nowicka, M., Krieg, C., Crowell, H.L., Weber, L.M., Hartmann, F.J., Guglietta, S., Becher, B., Levesque, M.P., and Robinson, M.D. (2017). CyTOF workflow: differential discovery in high-throughput high-dimensional cytometry datasets. *F1000Res.* 6, 748.
 78. Benjamini, Y., Krieger, A.M., and Yekutieli, D. (2006). Adaptive linear step-up procedures that control the false discovery rate. *Biometrika* 93, 491–507.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Anti-human CD1c (L161), Purified	Biolegend	Cat# 331502; RRID: AB_1088995
Anti-human CD3e (UCHT1), Purified	Biolegend	Cat# 317302; RRID: AB_571927
Anti-human CD4 (RPA-T4), Purified	Biolegend	Cat# 300502; RRID: AB_314070
Anti-human CD7 (M-T701), Purified	BD Bioscience	Cat# 555359; RRID: AB_395762
Anti-human CD8 (RPA-T8), Purified	Biolegend	Cat# 301002; RRID: AB_314120
Anti-human CD11b (M1/70), Purified	BioLegend	Cat# 101202; RRID: AB_312785
Anti-human CD11c (Bu15), Purified	BioLegend	Cat# 337202; RRID: AB_1236381
Anti-human CD14 (M5E2), Purified	Biolegend	Cat# 301802; RRID: AB_314184
Anti-human CD15 (HI98), Purified	Biolegend	Cat# 301902; RRID: AB_314194
Anti-human CD16 (3G8), Purified	Biolegend	Cat# 302002; RRID: AB_314202
Anti-human CD20 (2H7), Purified	Biolegend	Cat# 302302; RRID: AB_314250
Anti-human CD32 (Fun-2), Purified	Biolegend	Cat# 303202; RRID: AB_314334
Anti-human CD36 (5-271), Purified	Biolegend	Cat# 336202; RRID: AB_1279228
Anti-human CD38 (HIT2), Purified	Biolegend	Cat# 303502; RRID: AB_314354
Anti-human CD39 (A1), Purified	Biolegend	Cat# 328202; RRID: AB_940438
Anti-human CD40 (5c3), Purified	eBioscience	Cat# 14-0409-82; RRID: AB_467232
Anti-human CD45 (HI30), Purified	Biolegend	Cat# 304002; RRID: AB_314390
Anti-human CD64 (10.1), Purified	Biolegend	Cat# 305002; RRID: AB_314486
Anti-human CD66ace (ASL-32), Purified	Biolegend	Cat# 342302; RRID: AB_1626265
Anti-human CD68 (KP1), Purified	eBioscience	Cat# 14-0688-82; RRID: AB_11151139
Anti-human CD73 (AD2), Purified	Biolegend	Cat# 344002; RRID: AB_2154067
Anti-human CD86 (2331 (FUN-1)), Purified	BD Bioscience	Cat# 555655; RRID: AB_396010
Anti-human CD103 (SP301), Purified	Abcam	Cat# ab245746; RRID: AB_2884021
Anti-human CD123 (6H6), Purified	Biolegend	Cat# 306002; RRID: AB_314576
Anti-human CD141 (M80), Purified	Biolegend	Cat# 344102; RRID: AB_2201808
Anti-human CD163 (GHI/61), Purified	Biolegend	Cat# 333602; RRID: AB_1088991
Anti-human CD169 (7-239), Purified	Biolegend	Cat# 346002; RRID: AB_2189031
Anti-human CD192 (K036C2), Purified	Biolegend	Cat# 357202; RRID: AB_2561851
Anti-human CD206 (15-2), Purified	Biolegend	Cat# 321102; RRID: AB_571923
Anti-human CD274 (E1L3N), Purified	CST	Cat# 13684; RRID: AB_2687655
Anti-human CD370 (EPR22324), Purified	Abcam	Cat# ab223188; RRID: AB_2884022
Anti-human CXCR2 (48311), Purified	R&D Systems	Cat# MAB331-100; RRID: AB_2296102
Anti-human Granzyme B (GB11), Purified	Invitrogen Antibodies	Cat# MA1-80734; RRID: AB_931084
Anti-human HLA-DR (L243), Purified	Biolegend	Cat# 307602; RRID: AB_314680
Anti-human Indoleamine 2,3-dioxygenase (SP260), Purified	Abcam	Cat# ab228468; RRID: AB_2884023
Anti-human IL-6 (MQ-13A5), Purified	Biolegend	Cat# 501115; RRID: AB_2562841
Anti-human Ki-67 (B56), Purified	BD Bioscience	Cat# 556003; RRID: AB_396287
Anti-human PPARγ (14G4B17), Purified	Biolegend	Cat# 683402; RRID: AB_2572020
Anti-human Tim-3 (Polyclonal), Purified	R&D Systems	Cat# AF2365; RRID: AB_355235
Anti-human TMEM173 (SP339), Purified	Abcam	Cat# ab238796; RRID: AB_2884024
Anti-human VISTA (D1L2G), Purified	Fluidigm	Cat# 3160025D; RRID: AB_2811070

(Continued on next page)

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Continued		
Biological samples		
Peripheral blood mononuclear cells (PBMCs) and Serum samples from COVID-19 patients and healthy control individuals	Hospital Uster, Hospital Limmattal, Triemli Hospital, and the University Hospital Zurich (Switzerland)	N/A
Chemicals, peptides, and recombinant proteins		
Antibody Stabilizer PBS	Candor Bioscience	Cat# 131 050
Bis(2,2'-bipyridine)-4'-methyl-4-carboxybipyridine-ruthenium-N-succidimyl ester-bis(hexafluorophosphate) (96Ru, 98-102Ru, 104Ru)	Sigma Aldrich	Cat# 96631
Bismuth trichloride (209Bi)	Sigma Aldrich	Cat# 450723
maleimidomono-amido-DOTA (mDOTA)	Macrocyclics	Cat# B272
Cell Acquisition Solution	Fluidigm	Cat # 201240
Cell-ID Intercalator-Ir	Fluidigm	Cat# 201192B
DMSO	Sigma Aldrich	Cat# D2438
EDTA	StemCell Technologies, Inc.	Cat# EDS-100G
EQ Four Element Calibration Beads	Fluidigm	Cat# 201078
FcR Blocking Reagent, human	Miltenyi Biotec	Cat# 130-059-901
Indium (113In, 115In)	Fluidigm	N/A
Isothiocyanobenzyl-EDTA	Dojindo Laboratories	M030-10
Lanthanide (III) metal isotopes as chloride salts	Fluidigm	N/A
Lymphodex	Inno-Train Diagnostik GmbH	Cat# 002041500
Paraformaldehyde	Electron Microscopy Sciences	Cat# 15710
Saponin	Sigma Aldrich	Cat# S7900
SepMate™ PBMC Isolation Tubes	StemCell Technologies, Inc.	Cat# 85460
Yttrium (89Y)	Sigma Aldrich	N/A
Critical commercial assays		
IL-1β/IL-1F2 Quantikine ELISA Kit	R&D Systems	Cat# DLB50
IL-6 Quantikine ELISA Kit	R&D Systems	Cat# D6050
IFN γ Quantikine ELISA Kit	R&D Systems	Cat# DIF50
TNF α Quantikine HS ELISA Kit	R&D Systems	Cat# HSTA00D
Maxpar X8 Multimetal Labeling Kit	Fluidigm	Cat# 201300
Olink Inflammation panel	Olink® Proteomics	N/A
Deposited data		
Mass cytometry data	This paper	https://doi.org/10.17632/vyy8ttw7n9.1
Olink Proteomics data	This paper	https://doi.org/10.17632/vyy8ttw7n9.1
Software and algorithms		
CATALYST 3.12	Chevrier et al. ⁶³	http://bioconductor.org/packages/release/bioc/html/CATALYST.html
Cytobank	Kotecha et al. ⁶⁴	https://www.cytobank.org/
Diffusion map	Angerer et al. ⁶⁵	https://cran.r-project.org/web/packages/diffusionMap/index.html
FactoMineR	N/A	https://cran.r-project.org/web/packages/FactoMineR/FactoMineR.pdf
FlowJo v10.7.1	N/A	https://www.flowjo.com/
ggpubr	N/A	https://cran.r-project.org/web/packages/ggpubr/index.html
randomForest 4.6-14	Liaw and Wiener ⁶⁶	https://cran.r-project.org/web/packages/randomForest/index.html

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Rphenograph_0.99.1.9003	Levine et al. ⁶⁷	https://github.com/i-cyto/Rphenograph/
R 4.0.0	R Core Team, 2016	https://www.R-project.org
Rtsne 0.15	Van Der Maaten and Hinton ⁶⁸	https://github.com/jkrijthe/Rtsne

RESOURCE AVAILABILITY

Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Bernd Bodenmiller (bernd.bodenmiller@uzh.ch).

Materials availability

This study did not generate new unique reagents.

Data and code availability

The raw mass cytometry data and the Olink protein data generated during this study are available for download at Mendeley Data: <https://doi.org/10.17632/vyy8ttw7n9.1>.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Patients were recruited at the Hospital Uster, Hospital Limmattal, Triemli Hospital, and the University Hospital Zurich (Switzerland) from an outpatient as well as inpatient setting. The patients were eligible if they were symptomatic at the time of inclusion, had a newly diagnosed SARS-CoV-2 infection confirmed by quantitative reverse-transcriptase polymerase chain reaction (RT-qPCR), and were more than 18 years old. Healthy donors (n = 22) were recruited as controls. All participants, patients and healthy controls, signed a written informed consent. This non-interventional, observational study was approved by the Cantonal Ethics Committee of Zurich (BASEC #2016-01440) and performed in accordance with the Declaration of Helsinki. The sample size was based on availability of the samples. Investigators were blinded to disease severity, while performing experiments. While the analysis was cross-sectional, the patient outcomes were recorded prospectively after inclusion.

Standard clinical laboratory data (CRP, LDH, complete blood count with differential) was collected from the first day of hospitalization until the end of hospitalization. Patients were classified according to WHO guidance²³ into mild cases (mild illness and mild pneumonia) and (b) severe cases (severe pneumonia and ARDS). Pneumonia was considered severe if the patient required supplemental oxygen or had an oxygen saturation < 94%, in accordance with WHO guideline.²³ ARDS was classified as defined by the Berlin definition.⁶⁹ 36 of the severe COVID-19 patients required respiratory support at the time of sampling, such as supplemental oxygen, non-invasive ventilation or mechanical ventilation. A blood sample was collected from each patient, if possible coordinated with the usual care. For longitudinal analysis of SARS-CoV-2-specific immune responses, two subjects with mild COVID-19 and two subjects with severe COVID-19 were sampled twice during their disease course. All samples were processed in the same hospital laboratory.

At time of the manuscript, 70 COVID-19 patients and 22 healthy subjects were recruited. Four patients were excluded from analysis (two due to chronic lymphocytic leukemia and two due to unclarity whether the current disease was the primary infection). All healthy controls were tested for SARS-CoV-2 specific IgA and IgG antibodies and all were below the diagnostic reference value. We have previously described the SARS-CoV-2-specific antibody response in a subset of this cohort.⁷⁰ The complete characteristics of the cohort are given in [Table 1](#).

All patients received a standard clinical laboratory sampling and cytokines were measured. Furthermore, samples from 27 COVID-19 patients with mild, 29 with severe disease and all healthy subjects were processed for CyTOF. Samples from 26 COVID-19 patients with mild, 36 with severe disease and 17 healthy patients were evaluated with Olink proteomics. 54 patients and 17 healthy individuals were analyzed by CyTOF and Olink concomitantly. Longitudinal samples from patient CovP45 homogeneously failed the Olink incubation control, and could thus only be compared with each other, but were excluded from other analysis, together with one other sample which was not correctly processed prior to analysis. Three samples had less than 100 myeloid cells and were excluded from the monocyte analyses (samples: CovP17, CovP58, CovP74). Routine flow cytometry for NK cell quantification was performed on all samples in the accredited immunological laboratory at the University Hospital Zurich, as previously described.⁴⁶ The cohort characteristics and a selection of the Olink dataset are also shown in Adamo et al.⁴⁶ describing the T cell response of this cohort.

METHOD DETAILS

Blood collection and sample preparation for CyTOF

Venous blood samples were collected in BD vacutainer EDTA tubes, centrifuged, plasma removed, and the remaining blood diluted with an equal amount of PBS. This mixture was then layered into a SepMate tube (STEMCELL) filled with lymphodex (Inno-Traun Diagnostik GmbH) solution. The tube was centrifuged, and the PBMCs were washed with PBS and re-centrifuged. Aliquots of 1×10^6 PBMCs were then centrifuged, resuspended in 200 μ L 1.6% PFA (Electron Microscopy Sciences) diluted with RPMI 1640 medium, and fixed at room temperature for 10 min. Subsequently the reaction was stopped by adding 1 mL of cell staining medium (CSM, PBS with 0.5% bovine serum albumin and 0.02% sodium azide). The cells were centrifuged and the disrupted pellet was frozen at -80°C . The remaining PBMCs were frozen and stored in 1.5 mL 90% FBS, 10% DMSO at -80°C for at least 4 h. For long-term storage, the frozen cells were moved to liquid nitrogen. Reference cells for CyTOF analysis were derived from PBMCs from a healthy donor, which were stimulated with either 0.1 μ g/mL phytohemagglutinin for 24 h or 1 μ g/mL lipopolysaccharide and 1.5 μ g/mL monensin for 48 h. One-third of the PBMCs were unstimulated. The three sets of PBMCs were fixed and frozen as described above.

Mass cytometry barcoding

We ensured homogeneous staining by barcoding 1×10^6 PBMCs from each patient using a 60-well barcoding scheme consisting of unique combinations of four out of eight barcoding reagents as previously described.⁷¹ Six palladium isotopes (^{102}Pd , ^{104}Pd , ^{105}Pd , ^{106}Pd , ^{108}Pd , and ^{110}Pd , Fluidigm) were chelated to 1-(4-isothiocyanatobenzyl)ethylenediamine-N,N,N',N' tetraacetic acid (Dojino). Two indium isotopes (^{113}In and ^{115}In , Fluidigm) were chelated to 1,4,7,10-tetraazacyclododecane-1,4,7-tris-acetic acid 10-maleimide ethylacetamide (Dojino) following standard procedures.⁷² We titrated mass tag barcoding reagents to ensure equivalent staining for each reagent; final concentrations were between 50 nM and 200 nM. We used the previously described transient partial permeabilization approach to barcode the cells.⁷³ PBMCs from all samples were randomly loaded into wells of two 96-well plates and were analyzed in two independent experiments. Three standard samples were loaded onto each plate to enable assessment of inter-run variability. Cells were washed with 0.03% saponin in PBS (PBS-S, Sigma Aldrich) and incubated for 30 min with 200 μ L of mass tag barcoding reagents diluted in PBS-S. After washing three times with CSM, samples from each plate were pooled and stained with the antibody panel.

Antibodies and antibody labeling

The antibodies used in this study, including provider, clone, and metal tag, are listed in the [key resources table](#). Antibody conjugation was performed using the MaxPAR antibody labeling kit (Fluidigm). Upon conjugation, the yield of recovered antibody was assessed on a Nanodrop (Thermo Scientific) and then supplemented with Candor Antibody Stabilizer. We performed titrations to determine optimal concentrations of all conjugated antibodies. All antibodies used in this study were managed using the cloud-based platform AirLab.⁷⁴

Sample staining and data acquisition

After barcoding, pooled cells were incubated with FcR blocking reagent (Miltenyi Biotec) for 10 min at 4°C . Cells were stained with 400 μ L of the antibody panel per 10^7 cells for 45 min at 4°C . Cells were washed three times in CSM, once in PBS, resuspended in 0.4 mL of 0.5 μ M nucleic acid Ir- labeled intercalator (Fluidigm) and incubated overnight at 4°C . Samples were then prepared for CyTOF acquisition by washing the cells once in CSM, once in PBS, and once in water. Cells were then diluted to 0.5×10^6 cells/mL in Cell Acquisition Solution (Fluidigm) containing 10% EQ Four Element Calibration Beads (Fluidigm). Samples were acquired on a Helios upgraded CyTOF 2 in independent FCS files.

Cytokine ELISA

Serum was collected in BD vacutainer tubes. The samples were processed in the accredited immunological laboratory at the University Hospital Zurich. IL-1 β , IL-6, IFN γ , TNF α were quantified using R&D Systems ELISA kits.

Proteomics analysis using Olink

For serum proteomics, the commercially available proximity extension assay-based technology from Olink[®] Proteomics was used. Heat-inactivated plasma samples were sent to the Olink analysis laboratory in Davos, Switzerland for analysis using the inflammation panel. The Olink technology has been described previously.⁷⁵ Briefly, binding of paired cDNA-tagged antibodies directed against the targeted serum proteins lead to hybridization of the corresponding DNA oligonucleotides allowing subsequent extension by a DNA polymerase. The protein level is quantified using real-time PCR. Only samples that passed the quality control tests are reported. If expression was below the detection limit, the value reported is the lower limit of detection. Only proteins that were detectable in at least 50% of samples were used for subsequent analysis.

QUANTIFICATION AND STATISTICAL ANALYSIS

Mass cytometry data preprocessing and automated cell classification

Individual FCS files collected from each set of samples were pre-processed using a semi-automated R pipeline based on CATALYST to perform individual file concatenation, bead based normalization, compensation, debarcoding, and batch correction as previously

described.⁷⁶ During this process, inter-sample doublets were excluded based on the debarcoding scheme and intra-sample doublets were excluded based on DNA content. Spillover matrix for CyTOF compensation was assessed on all antibodies used in this study as previously suggested.⁶³

Upon pre-processing, a subset of 1,000 randomly selected cells from each sample were exported as FCS files and loaded on Cytobank. Immune cell subsets were manually gated according to the scheme described in Figure S1E. FCS files corresponding to each gate were exported and used to train a random forest classifier (R package randomForest), based on 500 trees and 6 variables tried at each split, leading to an OOB estimate of error rate of 0.43%. The resulting random forest model was used to assign each cell of the dataset to the predefined cell types. Based on a 40% assignment probability cutoff and a 20% delta cutoff, 98% of the cells were retained in the analysis.

Dimensionality reduction and clustering analysis

To visualize the high-dimensional data in two dimensions, the t-SNE algorithm was applied on data from a maximum of 1,000 randomly selected cells from each sample, with a perplexity set to 80, using the implementation of t-SNE available in CATALYST.⁷⁷ Channels which were not relevant for these cell subsets or which were affected by different background stainings across batches were excluded and not used for monocyte cluster characterization (CD15, CD66ace, CD3, CD45, CD8a, CD20, CXCR2, Granzyme B). Data were displayed using the ggplot2 R package or the plotting functions of CATALYST.⁷⁷

Visualization of marker expression on t-SNE maps was performed upon data normalization between 0 and 1. The maximum intensity was defined as the 99th percentile.

Clustering analysis of the myeloid and neutrophil subsets was performed using the R implementation of PhenoGraph run on all samples simultaneously, with the parameter k , defining the number of nearest neighbors, set to 100.⁶⁷ For the myeloid subset, clusters with less than 600 cells were excluded from the analysis.

In order to perform hierarchical clustering, pairwise distances between samples were calculated using the Spearman correlation or Euclidean distance, as indicated in the figure legend. Dendrograms were generated using Ward.2's method. Heatmaps were generated based on the pheatmap package.

To identify putative single-cell trajectories among monocyte clusters, we used the implementation of the diffusion map algorithm available in the R package scater using the default parameters and the same channels used to perform the t-SNE analysis. A maximum of 1,000 cells randomly selected from each cluster were included in the analysis.

The principal component analysis to identify the variations in the data described by the cluster frequencies or the combination of cluster frequencies and cytokine levels was performed based on the FactoMineR package. Data were visualized using the Factoextra R package.

Statistical analyses

The statistical analysis was performed using GraphPad Prism (version 8.4.3, GraphPad Software, La Jolla California USA) and R software (version 4.0.1) using the package "mgcv." Statistical normality testing was not performed. In general, non-parametric Mann-Whitney Wilcoxon test was used to test for differences between continuous variables and p values were adjusted for multiple testing using the Holm method. The Olink data was tested using parametric tests as recommended by the company. Categorical variables were compared using Fisher's exact test. Generalized additive models were used to evaluate relationships between time since symptom onset and different variables, with the number of knots used to represent the smooth term set at three. The correlation maps were displayed using the corrplot or pheatmap packages and the implemented hclust method.

The correlations between cellular subsets and the serum protein expressions were analyzed using non-parametric Spearman correlations. The significance threshold was set at an $\alpha < 0.05$. For the differential expression analysis, a false-discovery rate⁷⁸ of 1% was used as significance threshold, except for the late versus early comparison where 5% was used as indicated. The respective statistical tests used, as well as the exact n values, are given in each figure legend.

Cell Reports Medicine, Volume 2

Supplemental Information

A distinct innate immune signature marks progression from mild to severe COVID-19

Stéphane Chevrier, Yves Zurbuchen, Carlo Cervia, Sarah Adamo, Miro E. Raeber, Natalie de Souza, Sujana Sivapatham, Andrea Jacobs, Esther Bachli, Alain Rudiger, Melina Stüssi-Helbling, Lars C. Huber, Dominik J. Schaer, Jakob Nilsson, Onur Boyman, and Bernd Bodenmiller




Figure S1: Experimental design for mass cytometry data acquisition in two independent batches and quality assessment. Related to Figure 1.

(A) Schematic of the strategy used to collect mass cytometry data. Samples were analyzed in two batches. The indicated number of samples were barcoded and stained with the same antibody mix stored as frozen aliquots. The staining and the acquisition on the CyTOF were performed independently.

(B) Histograms of signal intensities for each marker included in the panel observed on the pooled references acquired in the two runs. Data were linearly scaled based on the 98th percentile. Shifts in background intensity were observed for CD16, CD66ace, and Granzyme B.

(C) t-SNE plot calculated for the three reference (naive PMC, LPS activated PBMC and PHA activated PBMC) samples included in each CyTOF run based on all markers included in the study, colored by batch.

(D) Dotplot of signal intensities for CD16 versus CD15 in reference sample.

(E) Manual gating strategy used to identify the main cell types used to train the random forest cell classifier.

(F) t-SNE plot as in Figure 1D of a random subset of 1'000 immune cells from each sample colored by normalized marker intensity (n=78 individuals).




Figure S2: In-depth characterization of the neutrophil and monocyte compartments. Related to Figure 2.

(A) t-SNE plots generated as described in Figure 2A based on a maximum of 1'000 neutrophils per patient colored by clusters identified with the PhenoGraph algorithm (n=78 individuals).

(B) Heatmap of the normalized marker expression for the PhenoGraph neutrophil clusters. Each cluster was manually assigned to three neutrophil subsets based on the negative, intermediate, or high expression of CD16. The assignment to the different neutrophil groups is indicated on the right side of the heatmap as "Phenotype".

(C) Overlaid histogram displaying the expression of CD16 (top panel) and Ki-67 (bottom panel) for the indicated neutrophil subsets. Arcsinh transformed intensities are shown for both markers on a linear axis. Values for each subset and marker correspond to the median ion row count

(D) Visualization of monocytes clusters using first and second components of a diffusion map. Cells are colored by PhenoGraph clusters. The two branches leading to the CD169⁺ cells are shown with black arrows (n=78 individuals).

(E) Diffusion map of the monocyte subsets as described in D colored by normalized marker intensities (n=78 individuals).





Figure S3: In-depth characterization of the neutrophil and monocyte compartments. Related to Figure 3.

(A) Boxplots of frequencies of the indicated monocyte clusters in the different disease severities splitted by age group as indicated on the right (n=75 individuals).


(B) Boxplots of frequencies of the indicated monocyte clusters in the different disease severities splitted by gender as indicated on the right (n=75 individuals).

(C) Heatmap of correlations between monocyte and neutrophil clusters and myeloid immune subsets across the cohort. The colors indicate Pearson's correlation coefficients (n=75 individuals).

A



B



C




Figure S4: Disease status of patients with high cluster 4 frequency. Related to Figure 4.

(A) Scatter plot of M4 cluster frequencies relative to the time after symptom onset. Dots are colored by disease severity and shapes indicate hospitalization status. The cluster frequency is given in relation to the total monocytes in the PBMCs. The frequencies in healthy controls are shown as a reference on the left. The pseudo-time course was modeled using a generalized additive model for the disease severities separately (mild, blue lines; severe, red lines, n=75 individuals).

(B) Boxplots of frequencies of the indicated monocyte cell population identified based on manual gating as indicated in Figure 4D in the different disease severities. Statistical analyses were performed with a Mann-Whitney-Wilcoxon test corrected for multiple testing based on the Holm method and p-values are shown if the results were significant ($p < 0.05$, n=75 individuals).

(C) Scatter plot of manually gated cell subset percentages relative to the time after symptom onset. The dots are colored by disease grade at sampling time. The frequencies in healthy controls are shown as a reference on the left (n=75 individuals).




Figure S5: Association between serum protein levels, disease stages, and myeloid subsets. Related to Figure 5.

- (A) Scatter plots of expression of selected cytokines as measured by ELISA. The dots are colored by disease grade at sampling time. The expression levels of the healthy controls are shown as a reference on the left, with a horizontal line indicating the median. The pseudo-time course was modeled using a general additive model for the disease severities separately (mild, blue lines; severe, red lines, $n=19$ healthy, 28 mild and 38 severe).
- (B) Scatter plots of the expression of the indicated serum proteins versus the time after symptom onset. The expression is given as NPX on a \log_2 scale. The dots are colored by disease grade at sampling time. The expression levels in healthy controls are shown as a reference on the left, with a horizontal line indicating the median. The pseudo-time course was modeled using a general additive model for the disease severities separately (mild, blue lines; severe, red lines, 77 individuals).
- (C) Volcano plot of proteomics data for COVID-19 patients with mild vs. severe disease at early (top panel) and late (bottom panel) stages. An FDR of 5% was taken as cut-off for significance ($n=60$ individuals).
- (D) Scatter plots of expression of selected serum proteins relative to time after symptom onset binned as indicated. The expression is given as NPX on a \log_2 scale. The dots are colored by disease severity at sampling time. The mean expression levels of the healthy controls are shown as a dotted horizontal line. For each bin, the median and the standard error of the mean are shown in red (severe) and blue (mild). Statistical analyses were performed with a t-test corrected for multiple testing based on the Holm method and p-values are shown if the results were significant ($p < 0.05$, $n=60$ individuals).




Figure S6 : Association between serum protein levels and myeloid subsets over the course of the disease. Related to Figure 6.

(A) Heatmap of Pearson correlation coefficients for relationships between the different PhenoGraph clusters, myeloid immune cell subsets, and significant differentially expressed serum proteins. Black square identifies a set of serum proteins associated with CD169+ activated monocyte subsets (M10-M13). Pink square identifies a set of serum proteins associated with the disease related monocyte subsets M4 and M6 (n=70 individuals).

(B) Scatter plots of frequencies of the indicated clusters versus expression of selected serum proteins in individual patients as described in Figure 6C, but colored by time after symptom onset. Relationship between the two variables is visualized with a linear regression line and quantified using a Spearman's correlation coefficient (Rho) with the corresponding p-value. Fq, frequency.

(C) Scatter plots of frequencies of the indicated clusters versus expression of selected serum proteins in individual patients as described in Figure 6C, but colored by time after symptom onset. Relationship between the two variables is visualized with a linear regression line and quantified using a Spearman's correlation coefficient (Rho) with the corresponding p-value. Fq, frequency.

(D) Scatter plots of the expression of the indicated serum proteins versus the time after hospitalization of patients from a publicly available dataset (dataset by Rodriguez et al). The expression is given as NPX on a log2 scale. The dots are colored by ICU status. The expression levels in recovered patients are shown as a reference on the right. Dots from individual patients are connected with a black line. The pseudo-time course was modeled using a generalized additive model for the different ICU status separately (non ICU, light red lines; ICU, red lines). Adjusted R2 and p-values of generalized additive models are shown for both the ICU and non ICU groups (n=19 recovered and 17 longitudinal patients).

Supplementary Table 1: Clinical laboratory parameters. Related to Table 1.

Laboratory values	Healthy	Mild cases	Severe cases
C-reactive protein (mean ± SD)	1.21 ± 1.61	29.87 ± 51.60*	89.46 ± 81.23**
Lactate dehydrogenase (% > upper limit of normal)	0%	28%	73.53 %*
Hemoglobin (mean ± SD, [g/l])	139.88 ± 13.31	136.39 ± 15.85	131.61 ± 15.77
Absolute platelet count (mean ± SD, [G/l])	257.25 ± 60.50	203 ± 67.97	219.74 ± 117.14
Total white blood cell count (mean ± SD, [G/l])	5.74 ± 1.52	5.83 ± 2.90	6.65 ± 3.49
Monocytes (mean ± SD, [G/l])	0.42 ± 0.15	0.50 ± 0.36	0.45 ± 0.34
Neutrophils (mean ± SD, [G/l])	3.17 ± 1.03	3.74 ± 2.70	5.28 ± 3.36**
Eosinophils (mean ± SD, [G/l])	0.13 ± 0.08	0.04 ± 0.05*	0.03 ± 0.07**
Basophils (mean ± SD, [G/l])	0.04 ± 0.02	0.02 ± 0.03*	0.01 ± 0.02*
Lymphocytes (mean ± SD, [G/l])	1.95 ± 0.74	1.50 ± 0.69*	0.81 ± 0.44**
CD3- CD56 ^{bright} CD16 ^{dim} NK cells (mean ± SD, [cells/ul])	11.14 ± 5.65	8.19 ± 4.98	6 ± 4.39*
CD3- CD56 ^{dim} CD16 ^{bright} NK cells (mean ± SD, [cells/ul])	206.29 ± 107.13	165.96 ± 147.96	162.16 ± 103.69
* Indicates significance (p-value threshold <0.05) compared to the healthy, ** in the severe indicates significance in comparison to the healthy and the mild.			